The Identification of Key Gene Expression Signature and Biological Pathways in Metastatic Renal Cell Carcinoma

Overview

Journal J Cancer

Specialty Oncology

Date 2020 Mar 21

PMID 32194783

Citations 5

Authors

Lin Bao

Ye Zhao

Chenchen Liu

Qi Cao

Yu Huang

Ke Chen

Zhengshuai Song

Affiliations

Soon will be listed here.

Abstract

To investigate the potential mechanisms contributing to metastasis of clear cell renal cell carcinoma (ccRCC), screen the hub genes, associated pathways of metastatic ccRCC and identify potential biomarkers. The ccRCC metastasis gene expression profile GSE47352 was employed to analyze the differentially expressed genes (DEGs). DAVID was performed to assess Gene ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. The protein-protein interaction (PPI) network and modules were constructed. The function pathway, prognostic and diagnostic analysis of these hub genes was picked out to estimate their potential effects on metastasis of ccRCC. A total of 873 DEGs were identified (503 upregulated genes and 370 downregulated genes). Meanwhile, top 20 hub genes were displayed. GO analysis showed that the top 20 hub genes were enriched in regulation of phosphatidylinositol 3-kinase signaling, positive regulation of DNA replication, protein autophosphorylation, protein tyrosine kinase activity, etc. KEGG analysis indicated these hub genes were enriched in the Ras signaling pathway, PI3K-Akt signaling pathway, HIF-1 signaling pathway, Pathways in cancer, etc. The GO and KEGG enrichment analyses for the hub genes disclosed important biological features of metastatic ccRCC. PPI network showed the interaction of top 20 hub genes. Gene Set Enrichment Analysis (GSEA) revealed that some of the hub genes was associated with metastasis, epithelial mesenchymal transition (EMT), hypoxia cancer and adipogenesis of ccRCC. Some top hub genes were distinctive and new discoveries compared with that of the existing associated researches. Our analysis uncovered that changes in signal pathways such as Ras signaling pathway, PI3K-Akt signaling pathway, etc. may be the main signatures of metastatic ccRCC. We identified several candidate biomarkers related with overall survival (OS) and disease-free survival (DFS) of ccRCC patients. Accordingly, they might be novel therapeutic targets and used as potential biomarkers for diagnosis, prognosis of ccRCC.

Citing Articles

Screening of differential gene expression patterns through survival analysis for diagnosis, prognosis and therapies of clear cell renal cell carcinoma.

Ajadee A, Mahmud S, Hossain M, Ahmmed R, Ali M, Reza M PLoS One. 2024; 19(9):e0310843.

PMID: 39348357 PMC: 11441673. DOI: 10.1371/journal.pone.0310843.

Label-free quantitative proteomics reveals the mechanisms of Aurora kinase B in renal cell carcinoma.

Li Y, Yang Y SAGE Open Med. 2024; 12:20503121241228474.

PMID: 38516642 PMC: 10956137. DOI: 10.1177/20503121241228474.

Diagnostic and Prognostic Biomarkers in Renal Clear Cell Carcinoma.

Weaver C, Bin Satter K, Richardson K, Tran L, Tran P, Purohit S Biomedicines. 2022; 10(11).

PMID: 36428521 PMC: 9687861. DOI: 10.3390/biomedicines10112953.

Development and Validation of a Prognostic Gene Signature in Clear Cell Renal Cell Carcinoma.

Zhan C, Wang Z, Xu C, Huang X, Su J, Chen B Front Mol Biosci. 2021; 8:609865.

PMID: 33968978 PMC: 8098777. DOI: 10.3389/fmolb.2021.609865.

HI-511 overcomes melanoma drug resistance targeting AURKB and BRAF V600E.

Chang X, Zhang T, Wang Q, Rathore M, Reddy K, Chen H Theranostics. 2020; 10(21):9721-9740.

PMID: 32863956 PMC: 7449901. DOI: 10.7150/thno.44342.

References

Liu M, Xu Z, Du Z, Wu B, Jin T, Xu K . The Identification of Key Genes and Pathways in Glioma by Bioinformatics Analysis. J Immunol Res. 2018; 2017:1278081. PMC: 5736927. DOI: 10.1155/2017/1278081. View

Li J, Guo L, Ai Z . An integrated analysis of cancer genes in clear cell renal cell carcinoma. Future Oncol. 2017; 13(8):715-725. DOI: 10.2217/fon-2016-0473. View

Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J . STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2014; 43(Database issue):D447-52. PMC: 4383874. DOI: 10.1093/nar/gku1003. View

Makohon-Moore A, Zhang M, Reiter J, Bozic I, Allen B, Kundu D . Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat Genet. 2017; 49(3):358-366. PMC: 5663439. DOI: 10.1038/ng.3764. View

Deng Z, Ma S, Zhou H, Zang A, Fang Y, Li T . Tyrosine phosphatase SHP-2 mediates C-type lectin receptor-induced activation of the kinase Syk and anti-fungal TH17 responses. Nat Immunol. 2015; 16(6):642-52. PMC: 4439382. DOI: 10.1038/ni.3155. View

Dos Santos E, Carneiro-Lobo T, Aoki M, Levantini E, Basseres D . Aurora kinase targeting in lung cancer reduces KRAS-induced transformation. Mol Cancer. 2016; 15:12. PMC: 4739397. DOI: 10.1186/s12943-016-0494-6. View

He S, Shu L, Zhou Z, Yang T, Duan W, Zhang X . Inhibition of Aurora kinases induces apoptosis and autophagy via AURKB/p70S6K/RPL15 axis in human leukemia cells. Cancer Lett. 2016; 382(2):215-230. DOI: 10.1016/j.canlet.2016.08.016. View

Yang S, Li W, Dong F, Sun H, Wu B, Tan J . KITLG is a novel target of miR-34c that is associated with the inhibition of growth and invasion in colorectal cancer cells. J Cell Mol Med. 2014; 18(10):2092-102. PMC: 4244023. DOI: 10.1111/jcmm.12368. View

Escudier B, Eisen T, Stadler W, Szczylik C, Oudard S, Siebels M . Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356(2):125-34. DOI: 10.1056/NEJMoa060655. View

10.

Boeckx C, Op de Beeck K, Wouters A, Deschoolmeester V, Limame R, Zwaenepoel K . Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins. Cancer Lett. 2014; 354(2):365-77. DOI: 10.1016/j.canlet.2014.08.039. View

11.

Shin J, Kim T, Kim H, Kim H, Suh M, Lee S . Aurkb/PP1-mediated resetting of Oct4 during the cell cycle determines the identity of embryonic stem cells. Elife. 2016; 5:e10877. PMC: 4798952. DOI: 10.7554/eLife.10877. View

12.

Chen B, Ding Y, Liu F, Ruan J, Guan J, Huang J . Tiam1, overexpressed in most malignancies, is a novel tumor biomarker. Mol Med Rep. 2011; 5(1):48-53. DOI: 10.3892/mmr.2011.612. View

13.

Gaudet P, Skunca N, Hu J, Dessimoz C . Primer on the Gene Ontology. Methods Mol Biol. 2016; 1446:25-37. PMC: 6377150. DOI: 10.1007/978-1-4939-3743-1_3. View

14.

Stengel K, Zheng Y . Cdc42 in oncogenic transformation, invasion, and tumorigenesis. Cell Signal. 2011; 23(9):1415-23. PMC: 3115433. DOI: 10.1016/j.cellsig.2011.04.001. View

15.

Jonasch E, Hasanov E, Corn P, Moss T, Shaw K, Stovall S . A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma. Ann Oncol. 2017; 28(4):804-808. PMC: 5834088. DOI: 10.1093/annonc/mdw676. View

16.

Qiu B, Ackerman D, Sanchez D, Li B, Ochocki J, Grazioli A . HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma. Cancer Discov. 2015; 5(6):652-67. PMC: 4456212. DOI: 10.1158/2159-8290.CD-14-1507. View

17.

Kanehisa M . The KEGG database. Novartis Found Symp. 2003; 247:91-101; discussion 101-3, 119-28, 244-52. View

18.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

19.

Liu J, Zeng Q, Cao P, Xie D, Chen X, Yang F . RIPK4 promotes bladder urothelial carcinoma cell aggressiveness by upregulating VEGF-A through the NF-κB pathway. Br J Cancer. 2018; 118(12):1617-1627. PMC: 6008479. DOI: 10.1038/s41416-018-0116-8. View

20.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View